VVD-159642 / Bayer - LARVOL DELTA

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: Vividion Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors (Businesswire) - "Vividion Therapeutics...announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers....The new Phase I study (NCT06804824) will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either sotorasib or trametinib in patients with advanced solid tumors."

Trial status • Solid Tumor

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=220 | Not yet recruiting | Sponsor: Vividion Therapeutics, Inc.

New P1 trial • Oncology • Solid Tumor

Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting (Bayer Press Release) - "Bayer and Vividion Therapeutics, Inc. (Vividion) will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2024 Annual Meeting....During the New Drugs on the Horizon session Bayer will introduce actinium-225 (225Ac)-PSMA-Trillium....The data presented will include preclinical in vitro and in vivo characterization....Another abstract will highlight the synergistic anti-cancer effects of targeted alpha therapy radium-223 dichloride (Xofigo) in combination with darolutamide in preclinical prostate cancer models....Vividion will present its latest research on the development and characterization of novel preclinical covalent inhibitors of the RAS-PIK3CA interaction, preventing RAS mediated activation of PIK3CA."

Preclinical • Metastatic Castration-Resistant Prostate Cancer